Global Urinary Incontinence Treatment Drugs Market, By Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence, and Other Incontinence Type), By Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 4.41 Bn in 2023, and is expected to exhibit a CAGR of 3.4% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Key market players are focusing on adoption of growth strategies such as launch of new products, and this is expected to drive the global urinary incontinence treatment drugs market growth. For instance, in April 2021, Urovant Sciences, a biopharmaceutical company, announced the commercial U.S. launch of GEMTESA (vibegron) 75 mg tablets, a beta-3 (β3) adrenergic receptor agonist, for the treatment of overactive bladder (OAB) with symptoms of urgency incontinence (UUI), urinary urgency, and urinary frequency in adults.
Global Urinary Incontinence Treatment Drugs Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
Supply chain and manufacturing activities had been disrupted globally due to lockdowns implemented by governments, and also faced problems regarding the transportation of drug products.
The coronavirus or COVID-19 outbreak that started from Wuhan, China, had spread across continents, affecting various industries globally. Supply of key materials had been severely disrupted due to forced quarantine, and lack of labors and raw materials. As the link between regional warehouses is not smooth, the transportation of raw materials between regions cannot be carried out successfully. This shortage of raw materials and components had affected the supply chain of the global urinary incontinence treatment drugs treatment market.
Global Urinary Incontinence Treatment Drugs Market: Key Developments
In 2020, Arcturus Therapeutics Holdings Inc., a clinical-stage messenger RNA medicines company, announced that it had initiated dosing in its Phase 1b study of ARCT-810 in patients with Ornithine Transcarbamylase (OTC) deficiency, the most common of the urea cycle disorders. ARCT-810 is an Arcturus’ flagship rare disease asset utilizing the company’s novel systemically administered mRNA therapeutic platform. Currently, the study is in the Phase II of the clinical trial, and it is expected to be completed by June 2024.
In January 2020, The Assistance Fund (TAF), an independent charitable patient assistance foundation, announced the launch of the Financial Assistance Program that focuses on providing high cost medicines at lower cost for patients suffering from urine cycle disorders in the U.S.
In May 2022, BlueWind Medical, Ltd., medical device company announced the completion of a Series B financing round of US$ 64Mn. Funds are being raised for the development of the innovative implantable tibial neuromodulation device RENOVA iStim, which is being studied for the treatment of urge incontinence or in combination with urinary urgency and/or urgency.
Browse 36 Market Data Tables and 26 Figures spread through 180 Pages and in-depth TOC on “Global Urinary Incontinence Treatment Drugs Market”- Forecast to 2030, Global Urinary Incontinence Treatment Drugss Market, By Incontinence Type (Urge Incontinence, Stress Incontinence, Over-flow Incontinence, Mixed Incontinence and Other Incontinence Type), By Drug Class (Anticholinergic/Antispasmodic Agents, Skeletal Muscle Relaxants, Antidepressants, Alpha Blockers, Topical Estrogens and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
Key Takeaways of the Global Urinary Incontinence Treatment Drugs Market:
- The global urinary incontinence treatment drugs market is expected to exhibit a CAGR of 3.4% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global urinary incontinence treatment drugss market.
- Among distribution channel, the retail pharmacies segment is expected to hold a dominant position in the global urinary incontinence treatment drugs market during the forecast period due to the technological advancements in the field of urinary incontinence treatment drugs. According to the Commonwealth Fund, in 2021, there were approximately 60,000 retail pharmacies in the U.S., out of which, one-third were independent pharmacies and two-thirds were retail chains, supermarkets, or mass retailers, which generate 56% of retail prescription revenue.
- Among region, North America is expected to be the dominant region in the global urinary incontinence treatment drugs market, owing to increasing prevalence of stress incontinence and increasing aging population susceptible to urological diseases. For instance, according to the Urology Care Foundation 2021, a quarter to a third of women in the U.S. suffer from stress urinary incontinence.
- Major players operating in the global urinary incontinence treatment drugs market are Johnson & Johnson, Pfizer Inc., Astellas Pharma, Inc., Allergan, Inc., Takeda Pharmaceutical Company Limited, Merck & Co., Inc., Sanofi S.A., IXALTIS, Bayer AG , elicept Therapeutics, Taiho Pharmaceutical, Cook MyoSite and Urovant Sciences GmbH.
